RxDoctor Payments Data

Ranga Rao, MD

Interventional Cardiology · Langhorne, PANPI 1184687402

Payments from drug & device makers

$7,040in general payments, 2019–2025

Across 328 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$959
  • Boston Scientific$784
  • Amgen$760
  • Novartis$584
  • AstraZeneca$478
  • Merck$430
  • plus $3K from 35 others

What the payments were for

  • Travel & lodging$1332%
  • Food & beverage$6,78996%
  • Education$1182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,040 in reported general payments places this provider in the 40th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$237,706
Medicare patients
565
Services billed
2,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$67,035
XareltoRivaroxaban33$33,624
Metoprolol Succinate60$1,012
Atorvastatin Calcium56$946
Torsemide41$548
Amiodarone Hcl11$464
Nitroglycerin16$417
Rosuvastatin Calcium27$416
ClopidogrelClopidogrel Bisulfate19$357
Carvedilol39$355
Metoprolol Tartrate30$330
Amlodipine Besylate39$304
Irbesartan14$282
Losartan Potassium18$243
Ezetimibe16$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$360$67,03549 claims
Johnson & JohnsonXarelto$959$33,62433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →